Lycia Therapeutics, Inc. is left out of our screens and market counts tonight, which cover US stocks priced at $5 or more and trading at least $1 million a day on average. Its read below still updates after every close.
Lycia Therapeutics, Inc.
Every stock that changed stage on Oct 23, 2026 →
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune,… More about the company
Pro read
ProOur read
Setup score
Momentum
Is LYCA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LYCA among Biotechnology
All 237 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | IOVA | Stage 2 · wk 20 | 99 | −37.6% |
| 2 | SLS | Stage 3 · wk 6 | 99 | −23.7% |
| 3 | MRNA | Stage 2 · wk 19 | 99 | +12.4% |
| 4 | SYRE | Stage 3 · wk 6 | 99 | +7.1% |
| 5 | TWST | Stage 2 · wk 41 | 99 | −31.6% |
| 6 | KOD | Stage 2 · wk 5 | 99 | +5.4% |
| 7 | ERAS | Stage 3 · wk 6 | 99 | −0.5% |
| 8 | CLYM | Stage 3 · wk 5 | 99 | −11.8% |
Against its industry
Biotechnology · 592 companies we cover
- Profit margin0.0%
Wider margin than 18%
- Debt to equity0.02x
Less debt than 71%
- Dividend yield0.00%
Higher yield than 0%
Lycia Therapeutics: quick answers
Which sector and industry is Lycia Therapeutics in?
Lycia Therapeutics is in the Biotechnology industry, part of the Health Care sector. 187 stocks in Health Care are in Stage 2, 37.4% of the sector. See the Stage 2 stocks in Biotechnology
About this companyHealth Care· Biotechnology
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease. Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-11-03. Past data patterns are not indicative of future results. This page is a data analytics tool only.